Mandate

Vinge represented affiliates of American Industrial Partners in entering into an agreement to acquire Veoneer’s Restraint Control Systems business from SSW Partners

Veoneer is the world leader in automotive electronic restraint control systems and has sold more than 1 billion electronic control units and crash sensors. Veoneer’s scalable, best-in-class restraint control systems are saving lives by mitigating the effects of car crashes. In 2023, the company’s products are part of more than 40 scheduled vehicle launches. The company has approximately 2,700 employees in 11 countries.

AIP is a middle market private equity firm focused on industrial businesses. The firm manages over $16 billion on behalf of its limited partners and invests in the aerospace and defense, automotive, building products, capital goods, chemicals, industrial services, industrial technology, logistics, metals and mining, transportation and other sectors.

Vinges team consisted of Ulrich Ziche (M&A), Daniel Wendelson, Hilda Ivarsson, Alva Chambert (EU, Competition and Regulatory), Simon Söderholm (Employment & Benefits) and Marcus Eklund (Investigations & International Disputes).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026